Anti-human FceR2 / CD23 (Lumiliximab Biosimilar) Beta chemokine receptor-like 1 : IHC0181R

: IHC0181R

causing substantial fluorophore deposition at the antigen–antibody binding site and thereby amplifying the signal

Binding of SCF by the c-Kit receptor leads to homodimerization of the receptor and the activation of signalling pathways such as PI-3

These modifications include the covalent attachment of methyl or acetyl groups to lysine and arginine amino acids and the phosphorylation of serine or threonine

Anti-human FceR2 / CD23 (Lumiliximab Biosimilar) Beta chemokine receptor-like 1 : IHC0181RApplication ELISA, Bioactivity: FACS, Functional assay, Research in vivo Reactivity Human Target Target Name FceR2 CD23 Target Uniprot P06734 Overview Catalog# BIO0588SM Product Name Anti human FceR2 CD23 (Lumiliximab Biosimilar) Specifications Conjugation None Clone# Lumiliximab Formulation 100 mM Pro Ac 20mM Arg pH 5. 0 Storage For long term storage, the produce should be stored at 20 or lower. Reconstitution Dissolve with sterile ddH2O